Key result
Deep venous thrombosis and cutaneous leukocytoclastic vasculitis after age 50 are associated with occult cancer, while cancer procoagulant showed 80% sensitivity and 83% specificity as a marker.
Why the study?
Do clinical clues and laboratory assays like cancer procoagulant help in the diagnosis of occult cancer in patients with unexplained thromboembolism?
Do clinical clues and laboratory assays like cancer procoagulant help in the diagnosis of occult cancer in patients with unexplained thromboembolism?
Unexplained deep venous thrombosis, especially with specific clinical clues like age >50 or resistance to warfarin, increases the probability of occult cancer, though extensive screening is not cost-efficient.
Clinical clues may prompt selective occult cancer evaluation in unexplained DVT; leaves open validation of cancer procoagulant as a screening tool.
BACKGROUND Unexplained thromboembolism may be an early indicator of the presence of a malignant tumor before signs and symptoms of the tumor itself become obvious. METHODS A survey of the MEDLINE data-base was conducted concerning cancer-associated vascular disorders and their role in the diagnosis of hidden cancer. The spectrum of vascular disorders hearalding occult cancer and the associated laboratory abnormalities were scrutinized. RESULTS Deep venous thrombosis was associated with a significantly higher frequency of malignancy during the first 6 months after diagnosis. Malignancies were found using simple clinical and diagnostic methods; additional screening was not cost-efficient. Other signs associated with deep venous thrombosis that increased the probability of an occult cancer were age older than 50 years, multiple sites of venous thrombosis, associated venous and arterial thromboembolism, thromboembolism resistant to warfarin therapy, and paraneoplastic syndrome. Among vascular syndromes, only cutaneous leukocytoclastic vasculitis presenting after the age of 50 years was consistently associated with cancer. Preliminary data with an antigen specific to tumor tissue, the cancer procoagulant, suggested its possible role as a tumor marker. The sensitivity for all samples analyzed from cancer patients was 80% and the specificity was 83%. CONCLUSIONS Data from the literature enabled us to outline clinical clues that might distinguish patients with cancer-associated vasculopathies from those unaffected by malignancies. Preliminary data with an antigen specific to tumor tissue, the cancer procoagulant, suggested its possible role in detecting early stage cancer. However, large-scale prospective studies are not currently available to evaluate the role of these clues and laboratory assays in the diagnosis of early stage cancer. Cancer 1996;77:1759-67.
No takes yet. Share an insight, caveat, or question.
Naschitz et al. (1996) conducted a review in Cancer-associated vascular disorders. Cancer-associated vascular disorders was evaluated on Diagnosis of hidden cancer. Deep venous thrombosis and cutaneous leukocytoclastic vasculitis after age 50 are associated with occult cancer, while cancer procoagulant showed 80% sensitivity and 83% specificity as a marker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Cancer